The Crestwood, KY-based company plans to raise $150M by offering 10.7 million shares at a price range of $13 to $15.
Apellis Pharmaceuticals, which is developing a novel protein inhibitor for autoimmune and inflammatory diseases, announced terms for its IPO on Monday.
The Crestwood, KY-based company plans to raise $150 million by offering 10.7 million shares at a price range of $13 to $15. Insiders intend to purchase $70 million worth of shares in the offering (47% of offering).
